Protagenic Therapeutics, Inc. has recently submitted its quarterly report, shedding light on its financial performance for the second quarter of 2026. This update is significant as it allows investors and stakeholders to gauge the company's progress and challenges in the competitive pharmaceutical industry.

Company Overview

Protagenic Therapeutics, Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company is listed on the OTC exchange under the ticker PTIX. Established in Delaware, Protagenic has undergone several name changes, with its most recent being in 2009 when it transitioned from Atrinsic, Inc.

What the Filing Says

The filing, dated November 6, 2026, provides a comprehensive overview of the company's financial status as of September 30, 2026. While specific financial figures were not disclosed in the available text, it is expected that the report will include critical metrics such as revenue, expenses, and net income, which are essential for evaluating the company's performance.

Impact on Stakeholders

This quarterly report is particularly relevant for investors, analysts, and competitors in the pharmaceutical preparations industry. Stakeholders will be keen to understand how Protagenic's performance aligns with market expectations and how it positions itself against peers in the sector.

What's Next

The filing does not specify what happens next for Protagenic Therapeutics. However, stakeholders will likely await further updates or additional filings that may provide more detailed insights into the company's strategic direction and operational adjustments.

Source: SEC Accession Number 0001493152-26-050425